Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Advaxis, Inc. (ADXS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 3.43 M | 41 M | 16.58 M | 7.53 M | |
| 2022 | 234 K | -25,196,000 | 2.3 M | 25.93 M | 25.76 M |
| 2021 | 681 K | -41,574,000 | 7.89 M | 46.78 M | 43.26 M |
| 2020 | 469 K | -19,161,000 | 8.35 M | 38.53 M | 27.85 M |
| 2019 | 469 K | -16,426,000 | 5.6 M | 20.05 M | 17.69 M |